NIF is delighted about the news of Melbourne-based respiratory imaging 4DMedical’s recent significant capital raise of $150 million, as a NIF collaborator since the company’s founding.
Headquartered in Melbourne since it was founded in 2012, the company has been recognised for its part in enabling essential work such as with NIF users A/Prof Martin Donneley and A/Prof David Parsons investigating new treatments for cystic fibrosis, also highlighted in their teams’ award of the Eureka Prize for Excellence in Interdisciplinary Scientific Research for developing and applying new methods of x-ray imaging to measure lung health.
Three NIF partners host 4DMedical instruments across our national network of sites – a large animal scanner, a small animal scanner and a human lung scanner – that help bring foundational science to clinicians for the benefit of Australian people’s health.
The small animal scanner was 4DMedical’s first instrument on offer, and NIF was 4DMedical’s first customer for it. It now offers research insights into areas such as foetal blood flow and growth, among many others. That instrument is located at SAHMRI.
Its high-performing lung-imaging technology (CT:VQ™) has been taken up extensively in the US, ready for accelerated commercialisation, which offers non-invasive 3D imaging scans of lung function minus radioactive tracers and contrast dyes.
The CT:VQ technology’s US regulatory clearance, institutional interest and new capital means its scientific potential offers conversion into real-world impacts for patients.
We congratulate the 4DMedical team on this latest success, and look forward to being a part of its continued successes.